Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics股价上涨,公司宣布在加州大学旧金山分校进行的RIDGE-1第10亿期临床试验中为首位患者注射了TN-401基因疗法。
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics的股票在公司宣布其在加利福尼亚大学旧金山分校的RIDGE-1阶段临床试验中对首名患者进行了TN-401基因疗法给药后,交易价格上涨。